Related Experiment Video

Updated: Jun 3, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K

Belzutifan for renal cell carcinoma: Balancing regulatory approval with societal and patient impact

Jad Chahoud1, Pavlos Msaouel2

  • 1Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.

Med (New York, N.Y.)
|January 11, 2025
PubMed

Insights

Belzutifan showed improved progression-free survival in advanced renal cell carcinoma (RCC) compared to everolimus. However, it did not meet the overall survival endpoint, indicating challenges for new RCC drug development.

Area of Science:

  • Oncology
  • Clinical Trials
  • Renal Cell Carcinoma Research

Background:

  • Advanced renal cell carcinoma (RCC) remains a significant clinical challenge.
  • Current treatment options for advanced RCC have limitations, necessitating novel therapeutic strategies.
  • Belzutifan and everolimus represent targeted therapy approaches for advanced RCC.

Purpose of the Study:

  • To evaluate the efficacy and safety of belzutifan compared with everolimus in patients with advanced renal cell carcinoma (RCC).
  • To assess progression-free survival (PFS) and overall survival (OS) as co-primary endpoints in the LITESPARK-005 trial.

Main Methods:

  • The LITESPARK-005 trial was a randomized, controlled study.
  • Patients with advanced RCC received either belzutifan or everolimus.
  • Key endpoints included progression-free survival and overall survival.

Main Results:

  • Belzutifan demonstrated a statistically significant improvement in progression-free survival (PFS) compared to everolimus.
  • The study did not meet the co-primary endpoint of overall survival (OS) improvement with belzutifan.
  • Adverse events and treatment tolerability were also assessed.

Conclusions:

  • Belzutifan offers a PFS benefit for patients with advanced RCC but does not improve OS in this trial.
  • The findings underscore the complexities of drug development in advanced RCC, including the need for robust OS data.
  • Further research is needed to identify predictive biomarkers and address accessibility and financial toxicity associated with novel therapies.

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.5K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
62
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
52
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
117
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels01:31

Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels

Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
167